Home・Aktien・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Geschlossen

BrancheGesundheitswesen

100.31 -0.99

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

99.43

Max

101.41

Schlüsselkennzahlen
By Trading Economics
Einkommen	80M 230M
Verkäufe	104M 481M
KGV Branchendurchschnitt	30.182 57.002
EPS	2.17
Gewinnspanne	47.799
Angestellte	423
EBITDA	100M 320M

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	-7.9% downside

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.9B 12B
Vorheriger Eröffnungskurs	101.3
Vorheriger Schlusskurs	100.31

Nachrichtenstimmung

By Acuity

26%

74%

77 / 340 Ranking in Healthcare

Halozyme Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Halozyme Therapeutics Inc Prognose

Kursziel

By TipRanks

-7.9% Nachteil

12-Monats-Prognose

Durchschnitt 93.75 USD -7.9%

Hoch 115 USD

Tief 57 USD

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Halozyme Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

8 ratings

Buy

Halten

Sell

Basierend auf 8 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Halozyme Therapeutics Inc – Dist abgegeben haben.

Stimmung

By Acuity

77 / 340 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.